Cyxone reaches important milestone regarding mechanism of action

Cyxone (publ), a biotech company in autoimmune diseases, has reached an important milestone for the drug candidate rabeximod. Recently, the biological target protein for rabeximod was identified, a finding that has now been confirmed in an independent scientific analysis. This important milestone represents a major step forward for the project as the new knowledge contributes to an increased understanding of the drug's mechanism of action and confirms its First-in-Class status.

Rabeximod is an immunomodulatory drug that has shown selectivity for pro-inflammatory macrophages and dendritic cells, which are cells that are central to the disease process in rheumatoid arthritis. Since the discovery of rabeximod in 2003, it has been documented how the drug significantly inhibits key pro-inflammatory processes in these disease-driving cells, but without having a detailed picture of the drug's target protein. The new research results now provide a much more detailed insight into the drug's mechanism of action.

” The new research findings are a very important step forward for the rabeximod project. We now have a much better idea of how the drug works in the cells. The results show that rabeximod has a unique mechanism of action (First-in-Class) that also provides a background to the favorable safety profile documented for the drug. Rabeximod is a mature and well-built project in Phase 2 where a comprehensive data package from pharmacological, preclinical and clinical studies, as well as already established manufacturing processes, has been supplemented with new patent protection and now with the last piece of the puzzle regarding the mechanism of action. We are, of course, delighted to now be able to straighten out this last question mark and thus move forward with a much more complete project”, says Carl-Magnus Högerkorp, CEO of Cyxone.

Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com